跳至主導覽 跳至搜尋 跳過主要內容

Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining IKZF1plus and Day 15 MRD positivity

  • Hsi Che Liu
  • , Ying Jung Huang
  • , Tang Her Jaing
  • , Kang Hsi Wu
  • , Shih Hsiang Chen
  • , Shih Chung Wang
  • , Ting Chi Yeh
  • , Chih Cheng Hsiao
  • , Te Kau Chang
  • , Hsiu Ju Yen
  • , Fang Liang Huang
  • , Pei Chin Lin
  • , Jen Yin Hou
  • , Jiunn Ming Sheen
  • , Yu Mei Liao
  • , Tsung Yen Chang
  • , Yu Chieh Chen
  • , Shyh Shin Chiou
  • , Chao Ping Yang
  • , Ching Hon Pui
  • Der Cherng Liang, Lee Yung Shih*
*此作品的通信作者
  • Mackay Memorial Hospital Taiwan
  • Chang Gung Memorial Hospital
  • Chang Gung University
  • Chung Shan Medical University
  • Changhua Christian Children's Hospital
  • China Medical University Children Hospital
  • National Yang Ming Chiao Tung University
  • Veterans General Hospital-Taichung Taiwan
  • Kaohsiung Medical University
  • St. Jude Children Research Hospital
  • University of Tennessee Health Science Center

研究成果: 期刊稿件 › 文章 › 同行評審

7 引文 斯高帕斯(Scopus)

摘要

This study investigates the potential utility of IKZF1 deletion as an additional high-risk marker for paediatric acute lymphoblastic leukaemia (ALL). The prognostic impact of IKZF1 status, in conjunction with minimal/measurable residual disease (MRD), was evaluated within the MRD-guided TPOG-ALL-2013 protocol using 412 newly diagnosed B-ALL patients aged 1–18. IKZF1 status was determined using multiplex ligation-dependent probe amplification. IKZF1 deletions, when co-occurring with CDKN2A, CDKN2B, PAX5 or PAR1 region deletions in the absence of ERG deletions, were termed IKZF1plus. Both IKZF1 deletion (14.6%) and IKZF1plus (7.8%) independently predicted poorer outcomes in B-ALL. IKZF1plus was observed in 4.1% of Philadelphia-negative ALL, with a significantly lower 5-year event-free survival (53.9%) compared to IKZF1 deletion alone (83.8%) and wild-type IKZF1 (91.3%) (p < 0.0001). Among patients with Day 15 MRD ≥0.01%, provisional high-risk patients with IKZF1plus exhibited the worst outcomes in event-free survival (42.0%), relapse-free survival (48.0%) and overall survival (72.7%) compared to other groups (p < 0.0001). Integration of IKZF1plus and positive Day 15 MRD identified a subgroup of Philadelphia-negative B-ALL with a 50% risk of relapse. This study highlights the importance of assessing IKZF1plus alongside Day 15 MRD positivity to identify patients at increased risk of adverse outcomes, potentially minimizing overtreatment.

原文英語
頁(從 - 到)1344-1353
頁數10
期刊British Journal of Haematology
卷204
發行號4
DOIs
出版狀態已出版 - 04 2024

文獻附註

Publisher Copyright:
© 2024 British Society for Haematology and John Wiley & Sons Ltd.

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining IKZF1plus and Day 15 MRD positivity」主題。共同形成了獨特的指紋。

引用此